WALKER WAYNE REMELL 4

What Happened
Wayne Remell, a director of PharmaCyte Biotech, was granted an award of 119,170 derivative securities on 2026-03-31. The Form 4 reports an acquisition price of $0.00 (no cash paid reported). The award is described in the filing as options that will vest in full on the date of the issuer’s next annual meeting of stockholders, subject to his continued service.

Key Details

• Transaction date: 2026-03-31; Form 4 filed 2026-04-02 (appears timely).
• Amount: 119,170 derivative shares/options; reported acquisition price: $0.00.
• Vesting: Options “shall vest in full” at the next annual meeting, conditional on continued service (Footnote F1).
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Transaction type: Award/Grant of a derivative security (code A).

Context
This was an equity award (derivative/options), not an open-market purchase or sale — there was no immediate cash sale or proceeds. Such awards are commonly used for director compensation and vesting is contingent on continued service; they do not by themselves indicate buying/selling sentiment.